A restricted label can often be an impediment to reimbursement, but Sarepta Therapeutics, Inc. is hoping that the limits on Elevidys, its new gene therapy for Duchenne muscular dystrophy, will pressure payers to set reimbursement policies quickly so no eligible boys age out the treatment window before being able to get coverage.
Key Takeaways
-
Sarepta will push for reimbursement so boys don’t age out of restricted Elevidys label
-
The company said conversations with payers have been positive
-
Elevidys
Elevidys (delandistrogene moxeparvovec-rokl) received an accelerated approval from the US Food and Drug Administration on 22 June for four- and five-year-old ambulatory
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?